Elevation Oncology, Inc. financial data

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 15 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2,276 % +26.7%
Debt-to-equity 55.14 % +2.1%
Return On Equity -74.68 % -25.8%
Return On Assets -48.14 % -24.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,215,795 shares +8.4%
Common Stock, Shares, Outstanding 59,223,729 shares +14.6%
Entity Public Float 135,200,000 USD +1.6%
Common Stock, Value, Issued 6,000 USD +20%
Weighted Average Number of Shares Outstanding, Basic 59,173,854 shares +14.2%
Weighted Average Number of Shares Outstanding, Diluted 59,173,854 shares +14.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29,462,000 USD +22%
General and Administrative Expense 16,213,000 USD +12.5%
Operating Income (Loss) -49,050,000 USD -27.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -47,951,000 USD -22%
Income Tax Expense (Benefit) 38,000 USD +5.6%
Net Income (Loss) Attributable to Parent -47,989,000 USD -21.9%
Earnings Per Share, Basic -1 USD/shares -9.5%
Earnings Per Share, Diluted -1 USD/shares -9.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60,494,000 USD -33.3%
Marketable Securities, Current 20,165,000 USD +50.2%
Assets, Current 82,194,000 USD -23.8%
Property, Plant and Equipment, Net 29,000 USD -40.8%
Other Assets, Noncurrent 0 USD -100%
Assets 82,223,000 USD -24.5%
Accounts Payable, Current 492,000 USD +13.1%
Accrued Liabilities, Current 3,744,000 USD +97.2%
Liabilities, Current 4,236,000 USD +81.5%
Liabilities 35,489,000 USD +7.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11,000 USD
Retained Earnings (Accumulated Deficit) -254,666,000 USD -23.2%
Stockholders' Equity Attributable to Parent 46,734,000 USD -38.4%
Liabilities and Equity 82,223,000 USD -24.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12,711,000 USD -32.8%
Net Cash Provided by (Used in) Financing Activities 30,250,000 USD +139%
Net Cash Provided by (Used in) Investing Activities 23,758,000 USD +14.8%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 59,316,859 shares +14.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11,030,000 USD -73.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60,494,000 USD -33.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 806,000 USD -9.1%
Deferred Tax Assets, Valuation Allowance 60,330,000 USD +31.3%
Deferred Tax Assets, Gross 60,334,000 USD +31.3%
Depreciation 5,000 USD -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47,978,000 USD -22.1%
Deferred Tax Assets, Operating Loss Carryforwards 26,500,000 USD +30.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 301,507,000 USD +6.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 4,000 USD +33.3%
Share-based Payment Arrangement, Expense 4,365,000 USD +57.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%